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Abstract
Gastric cancer (GC) is one of the most common and life-threatening types of malignancies. Identification of the
differentially expressed genes in GC is one of the best approaches for establishing new diagnostic and
therapeutic targets. Furthermore, these investigations could advance our knowledge about molecular biology
and the carcinogenesis of this cancer. To screen for the overexpressed genes in gastric adenocarcinoma, we
performed suppression subtractive hybridization (SSH) on gastric adenocarcinoma tissue and the correspond-
ing normal gastric tissue, and eight genes were found to be overexpressed in the tumor compared with those
of the normal tissue. The genes were ribosomal protein L18A, RNase H2 subunit B, SEC13, eukaryotic trans-
lation initiation factor 4A1, tetraspanin 8, cytochrome c oxidase subunit 2, NADH dehydrogenase subunit 4,
and mitochondrially encoded ATP synthase 6. The common functions among the identified genes include invol-
vement in protein synthesis, involvement in genomic stability maintenance, metastasis, metabolic improvement,
cell signaling pathways, and chemoresistance. Our results provide new insights into the molecular biology of
GC and drug discovery: each of the identified genes could be further investigated as targets for prognosis eva-
luation, diagnosis, treatment, evaluation of the response to new anticancer drugs, and determination of the
molecular pathogenesis of GC.
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Introduction
Being the second cause of cancer-related deaths,
gastric cancer (GC) continues to be one of the most
common and life-threatening types of malignancies
throughout the world.1 GC rate in the Middle East dif-
fers from very high in Iran to very low in Egypt.2,3
Owing to its aggressiveness and late diagnosis at
the advanced stage, GC has been considered a poor
prognosis cancer type.4 The most prevalent type of
GC is adenocarcinoma with two subtypes: the
well-differentiated or intestinal type and the poorly
differentiated or diffuse type. These two types of
GC have distinct molecular features.5 There are many
reports on the genetic and epigenetic alterations in
GC, which include alterations in tumor suppressor
genes (RUNX3), oncogenes (c-met), cell cycle regu-
lators (cyclin D1), DNA repair genes (hMLH1), and
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signaling molecules (TGFB1/2).6–8 A recent genome
expression analysis performed in Iranian population
has reported four isoforms of humanin (HN1, HN3,
HN6, and HN10) as the overexpressed genes in
GC.9 Identification of the differentially expressed
genes in GC is one of the best approaches for estab-
lishing new diagnostic and therapeutic targets.
Furthermore, these investigations could advance our
knowledge about molecular biology and the carcino-
genesis of GC.
There are two methodologies to survey gene
expression in cancer cells. In the first methodology,
including Northern blot and polymerase chain reac-
tion (PCR), a limited number of specific genes could
be studied. The second methodology, which includes
microarrays and subtractive hybridization, enables
simultaneous evaluation of differential gene expres-
sion in all genes, between two different conditions,
as described in our study between normal and can-
cerous tissues. The drawback associated with
microarrays is their probe-based analysis technique
that necessitates the pre-knowledge of the gene
sequences or the identity to be coded on the chip:
it means that novel genes could not be found in this
method. However, suppression subtractive hybridi-
zation (SSH) needs no prior knowledge of the gene
sequences: therefore, genes with novel functions in
cancer cells could be identified with this method.10
Systems biology is a new integrative approach used
in cancer biology research that concentrates on com-
plex interactions within biological systems with a
whole view. Transcriptomics, metabolomics, proteo-
mics, and high-throughput techniques are used to
collect data for the construction and validation of
models in systems biology.11,12
There are many studies on gene alterations that
have occurred in GC, but the data provided by these
investigations are not enough to elucidate the molecu-
lar pathogenesis of GC. Along with these studies,
toward establishing more data about the gene altera-
tions in GC and finding targets for drug discovery,
we performed SSH on gastric adenocarcinoma tissue
and the corresponding normal gastric tissue to inves-
tigate the gene overexpression in GC.
Methods
Sample collection
Human gastric tissue samples (normal and tumor)
were collected from a 64-year-old male patient who
underwent operation for gastric adenocarcinoma at
the Arad Hospital of Iran in October 2010. RNAla-
ter1 (Ambion, Austin, TX, USA) was used to stabi-
lize the RNA. In order to determine the tumor type
and metastasis, the discarded tissue samples were
examined by an experienced pathologist using hema-
toxylin–eosin (H&E) staining. The request for acqui-
sition of the gastric tissues was approved by the
Biologic Sampling Ethics Committee, Tehran Univer-
sity of Medical Sciences (TUMS), and a written con-
sent form was obtained from the patient before
surgery.
Total RNA extraction
Total RNA extraction was performed by acid–guani-
dium–chloroform method (Chomczynski and Sac-
chi, 1987) using TriPure Isolation Reagent (Roche
Applied Sciences, IN, USA) according to the manu-
facturer’s protocol. RNA concentration and purity
were determined using a biophotometer (Eppendorf,
Germany). A260 was used to determine the RNA
concentration and the A260/A280 ratio was used to
assess the RNA purity (the acceptable values for the
A260/A280 ratio were considered to be 1.9–2.1). In
addition, RNA was visually detected by staining the
18S and 28S RNAs on gel electrophoresis using ethi-
dium bromide.
mRNA isolation
mRNA isolation was done using the DynaBead1
mRNA Isolation kit (Invitrogen, CA, USA) from the
extracted total RNA following the manufacturer’s
protocol. First of all, equilibration of the DynaBeads
oligo(dT)25 was performed with 100 ml of binding
buffer (100 mM Tris–hydrochloric acid (Tris-HCl),
500 mM lithium chloride (LiCl), 10 mM ethylene-
diaminetetraacetic acid (EDTA), 1% lithium dodecyl
sulphate (LiDS), and 5 mM dithiothreitol (DTT)).
Total RNA was diluted with the binding buffer and
mixed with the equilibrated DynaBeads. This mix-
ture was then incubated at 37C for 5 min to allow
the hybridization between oligo(dT)25 and the
mRNA poly Aþ tail. The bead/mRNA complex was
washed using 200 ml of washing buffers A (10 mM
Tris–HCl, 0.15 M LiCl, 1 mM EDTA, and 0.1%
LiDS) and B (10 mM Tris–HCl, 0.15 M LiCl, and
1 mM EDTA). Finally, the elution buffer (10 mM
Tris–HCl) was used to elute mRNA from the beads.
Agarose gel electrophoresis (1%) was used to detect
the isolated mRNA.
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Subtracted library construction using SSH
The subtracted library was constructed using the
SSH method using the PCR-Select™ cDNA subtrac-
tion kit (Clontech, CA, USA) according to the man-
ufacturer’s protocols. To find the overexpressed
genes in GC, the normal gastric tissue was used as
the driver and the corresponding tumor tissue was
used as the tester. The tester and driver cDNAs were
synthesized using 2 mg of the mRNA isolated from
the two types of tissues being compared (normal and
tumor gastric tissues), and they were purified using
the phenol–chloroform extraction method. The puri-
fied tester and driver cDNAs were each digested
with Rsa I restriction enzyme to yield shorter,
blunt-ended molecules. The Rsa I-digested cDNA
was further purified using the phenol–chloroform
extraction method. Two populations of the tester
were prepared using adaptor 1 and adaptor 2R,
which were independently ligated to the tester
cDNA. Two steps of hybridization were performed
between the tester and excess amounts of the driver:
the hybridization step equalized and enriched the
differentially expressed sequences. In the first hybri-
dization step, the denaturation temperature was set
at 98C (1.5 min) for both driver and tester popula-
tions, and the hybridization temperature was set at
68C (8 h). For the second hybridization step, the
two first hybridization mixtures were mixed, fresh
denatured driver cDNA (98C for 1.5 min) was
added to this mixture and the hybridization tempera-
ture was set at 68C overnight. The entire popula-
tions of molecules were then subjected to primary
suppression PCR, which exponentially amplified
only the desired differentially expressed sequences.
Finally, the secondary PCR amplification was per-
formed using nested primers to further reduce any
background PCR products and enrich for differen-
tially expressed sequences. Table 1 represents the
sequences of the primers used for subtracted library
construction.
Analysis of subtraction efficiency
Real-time PCR was used to estimate the efficiency of
subtraction by comparing the abundance of a non-
differentially expressed gene (a housekeeping gene:
-actin) before and after subtraction. Table 1 repre-
sents the sequences of the -actin forward and reverse
primers. Reactions consisted of 10 ml SYBR Premix
Ex Taq (Takara, Japan), 1 ml cDNA, 0.8 ml each for-
ward and reverse primers (10 mM), 0.4 ml ROX dye,
and DEPC-treated water to a final volume of 20 ml.
The thermal program for the reaction was set at
95C for 10 min, followed by 40 cycles of 30 s at
95C, and 1 min at 60C. Melting curve analysis was
done by increasing the temperature from 65C to
95C in 0.1C/s increments for each fluorescence
reading, using the Step-One-Plus Apparatus (Applied
Biosystems, CA, USA). The relative expression of the
-actin gene in the subtracted and non-subtracted
samples was used in the calculation of the subtraction
efficiency.
Identification of the differentially
expressed sequences
The constructed library was purified with the PCR
Product Purification kit (Roche Applied Sciences,
IN, USA). The purified products were then cloned
into pUC19 plasmid vectors and transformed into
Escherichia coli NovaBlue competent cells (Nova-
gen, WI, USA). The primary verification of the ran-
domly selected positive colonies was performed by
colony PCR using N1 and N2R primers (Table 1).
Confirmed positive clones were subjected to plasmid
isolation by the High Pure Plasmid Isolation kit
(Roche Applied Sciences, IN, USA) and the purified
plasmids were then used for single direction DNA
sequencing with the BigDye Terminator Version 3.1
Sequencing kit and a 3730xl Automated Sequencer
(Applied Biosystems, CA, USA). Identification of the
differentially expressed sequences was performed by
Table 1. Primers for SSH and PCR analysis of the recombinant clones.
Primer name Primer sequence 50 to 30 Primer length Annealing temperature
N1 TCGAGCGGCCGCCCGGGCAGGT 22 68C
N2R AGCGTGGTCGCGGCCGAGGT 20
PCR primer 1 CTAATACGACTCACTATAGGGC 22 66C
-actin-F ATGGCCACGGCTGCTTCCAGC 21 60C
-actin-R CAGGAGGAGCAATGATCTTGA 21
SSH: suppression subtractive hybridization; PCR: polymerase chain reaction.
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similarity searches with a Basic Local Alignment
Search Tool (BLAST) (http://blast.ncbi.nlm.nih.gov/
Blast.cgi).
Results
Pathologic characteristics of the tissue
Histological results revealed that the tumor was a
moderately differentiated, mucin-producing type of
gastric adenocarcinoma located in the prepyloric area.
Local invasion to the lymph node was observed in two
of the six perigastric lymph nodes.
Total RNA extraction and mRNA isolation
A260 was used to determine the RNA concentration
and the A260/A280 ratio was used to assess the RNA
purity (Table 2). Since the gastric tumor tissue shows
high levels of mucin, the yield of RNA isolation
from this tissue was less than the normal one, and the
purity of the RNA was less than the acceptable value.
RNA was then visually detected on 1% agarose gel
(Figure 1).
Subtracted library construction by SSH
Tester and driver cDNAs were synthesized from the
isolated mRNA of the normal and tumor tissues and
they were analyzed with 1% agarose gel electrophor-
esis. Figure 2(a) shows the results of cDNA synthesis
(before and after purification). Figure 2(b) shows the
cDNA before and after restriction digestion which
indicates that Rsa I digestion was performed on the
cDNA and generated shorter sequences. Figure 2(c)
shows the products of the primary and secondary PCR
amplifications, indicating that we successfully con-
structed a putative subtracted cDNA library of GC
cells representing the overexpressed genes in this can-
cer. The library was between 100 to 1200 bp in size.
Analysis of subtraction efficiency
We evaluated the subtraction efficiency by compar-
ing the abundance of a housekeeping gene, -actin
before and after subtraction with real-time PCR anal-
ysis. The results indicated that -actin had an 8.9-
fold reduction in the subtracted library, compared
with the non-subtracted library, demonstrating that
the differentially expressed genes were enriched in
the subtracted library.
Identification of the differentially
expressed sequences
We used the SSH method to examine the differential
gene expression using human gastric adenocarcinoma
as the tester and the adjacent normal gastric tissue as
the driver, with specific enrichment for the overex-
pressed sequences in the adenocarcinoma tissue. The
constructed subtractive library was cloned into the
pUC19 plasmid vectors and transformed into Nova-
Blue cells. In total, 70 subtractive clones were
obtained and randomly picked for subsequent colony
PCR (Figure 3), sequencing and identification by
BLAST. Table 3 represents the identified genes in this
study as the overexpressed genes in GC.
Discussion
One of the goals of the gene expression profiling stud-
ies is to unravel the precise roles of the genes under
Table 2. Analysis of RNA concentration and purity.
Sample
Concentration
(mg/ml) A260/A280
Total RNA
Gastric normal tissue 4.25 1.96
Gastric tumor tissue 1.1425 1.7
mRNA
Gastric normal tissue 1 1.9
Gastric tumor tissue 0.9 1.8
Figure 1. RNA preparation. (a) Total RNA extracted from
normal (lane 1) and tumor (lane 2) gastric tissues. (b)
mRNA isolated from the total RNA from normal (lane 1)
and tumor (lane 2) gastric tissues.
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Figure 3. PCR analysis of the recombinant clones. Lanes 1–30: PCR products from different clones; lanes 26 and 28 were
false positive clones. L: DNA ladder. PCR: polymerase chain reaction.
Figure 2. The analysis on the subtracted library construction. (a) Analysis of ds cDNA synthesis. L: DNA ladder, 1: driver
cDNA before purification, 2: driver cDNA after purification, 3: tester cDNA before purification, and 4: tester cDNA after
purification. (b) Analysis of Rsa I digestion. 1: tester cDNA after digestion, 2: tester cDNA before digestion, 3: driver
cDNA after digestion, and 4: driver cDNA before digestion. (c) PCR amplification. L: DNA ladder, 2: primary PCR
amplification, and 3: secondary PCR amplification. PCR: polymerase chain reaction.
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normal and disease conditions to increase the knowl-
edge about the disease and improve the strategies used
in diagnosis, treatment, and prevention of the disease.
This study was focused on the overexpressed genes in
gastric adenocarcinoma as the most prevalent type of
cancer in Iran, and we used SSH as a high throughput
gene expression analysis method to identify the dif-
ferentially overexpressed genes. Eight genes were
identified, each of which could be further investigated
as targets for prognosis evaluation, diagnosis, treat-
ment, and determination of the molecular pathogen-
esis of GC. Furthermore, the biomarkers determined
by such studies can be applied in a system’s pharma-
cology framework to build predictive models of sig-
naling networks that control cell death and survival
in cancer cells.13
TSPAN8 or CO-029, a tumor associated antigen,
belongs to the tetraspanin superfamily that directly
regulates all of the cellular events related to tumor cell
migration and metastasis.14–19 The involvement of
TSPAN8 in cancer has been previously reported in
colorectal, gastric, esophageal, pancreatic, and liver
cancer analyses.20–23 The expression level of
TSPAN8 is associated with the poor prognosis of gas-
trointestinal cancer patients. TSPAN8 overexpression
in GC could be related to its role in cell migration and
metastasis: TSPAN8 facilitates metastasis by promot-
ing angiogenesis. Furthermore, due to its existence in
the blood, TSPAN8 could be used to evaluate the
patient response to new anticancer drugs.24
RPL18A is one of the 60S ribosomal proteins
(r-proteins). Many r-proteins serve as RNA chaper-
ones. Furthermore, they could organize the interac-
tions between the ribosome and mRNA/translation
factors.25 The gene expression alterations of many
r-proteins have been reported in many types of cancer
which could be due to two reasons: (1) changes in
r-proteins interrupt their roles in protein synthesis,
which could be the result or the trigger of tumorigen-
esis and (2) r-proteins directly participate in the
tumorigenesis by their extraribosomal roles. RPL18A
overexpression has been reported in colorectal can-
cer.26 Although different extraribosomal functions
have been reported for many r-proteins, but that of
RPL18A remains to be elucidated.27
COII, ND4 and ATP6 are mitochondrial genes
involved in oxidative phosphorylation (OXPHOS)
biochemical cascade: OXPHOS produces more than
90% of the cellular ATP. The fact that ATP decreases
in all cell death mechanisms indicates that energy
metabolism might have an important role in tumor
cell survival especially under stress conditions includ-
ing chemotherapy. Previous studies reported mutation
and deletion of mitochondrial genes including ND1,
ND5, D-loop, COXI, and ATP6 in GC and this is the
first report on the overexpression of ND4, COII, and
ATP6 in this type of cancer.28–35
RNASEH2B encodes the subunit B of the RNase
H2 enzyme which degrades RNA in the DNA/RNA
hybrids: these hybrids are formed during different
Table 3. Representative overexpressed genes in GC.
Gene name
Gene
ID
Cytogenetic
location Description Functions
RPL18A 6142 19p13 60S ribosomal protein L18a Translation and potential extraribosomal
function
TSPAN8 7103 12q14.1–
q21.1
Tetraspanin 8 Cell signaling, cell migration, cell invasion,
and angiogenesis
COII 4513 MT Cytochrome c oxidase subunit 2 (COII) Metabolic effect
ND4 4538 MT NADH dehydrogenase, subunit 4
ATP6 4508 MT Mitochondrially encoded ATP
synthase 6
EIF4A1 1973 17p13 Eukaryotic translation initiation
factor 4A1
Translation and mediating the transforming
effects
RNASEH2B 79621 13q14.3 Ribonuclease H2, subunit B; Aicardi-
Goutieres syndrome 2 protein;
RNase H2 subunit B
RNA degradation in DNA/RNA hybrids
(replication, transcription, etc.) and
genomic stability
SEC13 6396 3p25-p24 Protein SEC13 homologue Nuclear transport, COP-II coated vesicle
biogenesis, mitotic progression, and
genomic instability
GC: gastric cancer.
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processes in the cell including replication, transcrip-
tion, and telomere elongation. Therefore, RNase H2
is necessary for the maintenance of the genome integ-
rity and stability and is involved in DNA repair. DNA/
RNA hybrids have short time half-life but their patho-
logic accumulation leads to genomic instability which
correlates with the susceptibility to cancer.36–39 This is
the first report on RNASEH2B overexpression in GC.
EIF4A1 is an RNA helicase and a subunit of the
eIF4F complex which is involved in cap recognition
and is required for mRNA binding to the ribosome.
The transforming potential of other members of the
EIF4F complex has been demonstrated and it was
suggested that EIF4A1 has a mediating role in the
transforming effect of other members of the com-
plex.40–42 EIF4A1 overexpression has been reported
in melanoma and hepatocellular carcinoma.43,44
SEC13 is a constituent of the endoplasmic reticulum
and the nuclear pore complex (NPC). According to their
functions in the entry/exit control of themolecules to the
nucleus, NPCs have been suggested to be involved in
drug resistance. SEC13 involves in transforminggrowth
factor- (TGF-) signaling cascade due to its function
in the entry of the small mothers against decapentaple-
gic (SMAD) into the nucleus. Since the TGF- signal-
ing pathway is related to cancer, SEC13 might also be
associated with oncogenesis through the TGF--depen-
dent signal transduction cascade. In addition, SEC13 is
required for the maintenance of genomic stability dur-
ing mitosis. Its overexpression has been reported in
breast cancer cells.45–49
Common functions were observed among the
identified genes in this study including their involve-
ment in protein synthesis (EIF4A1 and RPL18A),
maintenance of genomic stability (SEC13 and RNA-
SEH2B), metastasis (TSPAN8), metabolic improve-
ment (CO-II, ND4 and ATP6), cell signaling
pathways (TSPAN8 and SEC13), and chemoresis-
tance (SEC13 and mitochondrial genes). However,
as a complementary survey, the study of the precise
roles of these eight identified genes in different
stages of GC pathogenesis is suggested, which might
lead us to find suitable targets for diagnosis and/or
treatment of this cancer. Furthermore, due to their
potential role in drug resistance, mitochondrial genes
and SEC13 could be investigated as targets to allevi-
ate chemoresistance, which is one of the main con-
cerns in the treatment of GC.
Although our results suggest the possibility of the
relevance between these new overexpressed genes and
gastric carcinogenesis, little is known about the relation
of these genes to GC. Furthermore, long-term follow-
up data for GC patients with a large sample size is
needed for evaluating these genes as a diagnostic or
prognostic marker. If the prognostic or predictive value
of these genes is confirmed, they could be considered
as factors to determine the treatment modality for gas-
tric carcinoma. An investigation on targeted manipula-
tion of expressions of these genes may provide the
possibility of new treatment modalities.
In summary, we screened the difference in gene
expression between gastric carcinoma and normal
gastric tissues using the SSH method. Our results
showed that eight genes including ND4, COII, ATP6,
RPL18A, RNASEH2B, EIF4A1, TSPAN8, and
SEC13 were involved in carcinogenesis. Their role
in gastric carcinogenesis and their diagnostic and
prognostic significances remain to be revealed.
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